KEYNOTE-826
Added nearly ten months of life for women with advanced cervical cancer and made immunotherapy part of first-line treatment.
Final analysis: OS 26.4 vs 16.8 months in all comers (HR 0.63) and 28.6 vs 16.5 months in PD-L1 CPS ≥1 (HR 0.60; JCO 2023). FDA approval October 2021 for CPS ≥1 disease. Bevacizumab was given to ~63% of patients at investigator discretion.
- Median 26.4 vs 16.8 months with Pembrolizumab + chemo ± bev compared with Placebo + chemo ± bev; about 9.6 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 37 percent lower chance of the event at any given time (hazard ratio 0.63, likely range 0.52 to 0.77).
- Median 28.6 vs 16.5 months with Pembrolizumab + chemo ± bev compared with Placebo + chemo ± bev; about 12.1 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 40 percent lower chance of the event at any given time (hazard ratio 0.6, likely range 0.49 to 0.74).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Persistent, recurrent, or metastatic cervical cancer, first line: pembrolizumab + platinum-paclitaxel ± bevacizumab vs placebo + chemotherapy ± bevacizumab. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
617 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survival (all comers)primary | Pembrolizumab + chemo ± bev | 308 | 26.4 months | 0.63 (0.52–0.77) | — | link |
| Placebo + chemo ± bev | 309 | 16.8 months | ||||
| Overall survival (CPS ≥1)primary | Pembrolizumab + chemo ± bev | — | 28.6 months | 0.6 (0.49–0.74) | — | link |
| Placebo + chemo ± bev | — | 16.5 months |
Pages like this
not linked directly; found by shared links- TrialKEYNOTE-B96 / ENGOT-ov65
Shares Combined positive score (CPS), Bevacizumab, Paclitaxel / nab-paclitaxel, PD-1.
- TrialBEATcc / ENGOT-Cx10 / GOG-3030
Shares Cisplatin, Bevacizumab, Paclitaxel / nab-paclitaxel, Cervical cancer.
- TrialCOMPASSION-16 / AK104-303
Shares Cisplatin, Bevacizumab, Paclitaxel / nab-paclitaxel, Cervical cancer.
- TrialKEYNOTE-590
Shares Combined positive score (CPS), PD-1, Pembrolizumab.
- CancerVulvar cancer
Shares Cisplatin, Combined positive score (CPS), Bevacizumab, Paclitaxel / nab-paclitaxel.
- TrialKEYNOTE-859
Shares Combined positive score (CPS), PD-1, Pembrolizumab.
- TrialKEYNOTE-048
Shares Combined positive score (CPS), PD-1, Pembrolizumab.
- TrialINTERLACE
Shares Cisplatin, Paclitaxel / nab-paclitaxel, Cervical cancer.